中偉股份(300919.SZ):與中創新航結成深度戰略合作伙伴關係
格隆匯9月23日丨中偉股份(300919.SZ)公佈,公司與中創新航科技股份有限公司(簡稱“中創新航”)於2022年9月22日簽署《戰略合作框架協議》。雙方就電池材料、新材料、鎳、鈷、鋰等領域開展共同投資、合作研發等多領域的合作,雙方均以優秀的企業理念與專業性,結成深度的戰略合作伙伴關係。
中創新航是專業從事鋰電池、電池管理系統及相關集成產品和鋰電池材料的研製、生產、銷售和市場應用開發的高科技企業。根據高工鋰電數據,按2022年上半年裝機量計,中創新航在國內第三方動力電池公司中排名第三,全球第三方動力電池企業中排名第七。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.